Research
FORUM TRANSCRIPT

Boston Scientific – Cardiovascular Portfolio Analysis & Outlook

  • Public Equity
  • Healthcare
  • North America
PREMIUM

Specialist

Former VP at Boston Scientific Corp

Agenda

  • Recent trends and developments within the cardiology device space, focusing on Boston Scientific (NYSE: BSX)
  • Boston’s Watchman market share defensibility vs Abbott’s (NYSE: ABT) Amplatzer Amulet
  • Efforts to re-enter structural heart market by 2024 with Acurate Neo2
  • Pricing dynamics and potential ASP erosion in drug-eluting stents
  • Product pipeline outlook and R&D allocation
  • 3-5-year outlook, potential M&A activity and expansion opportunities

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo